Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Total Therapy 2 examined the clinical benefit of adding thalidomide up-front to a tandem transplant regimen for newly diagnosed patients with multiple myeloma. When initially reported with a median follow-up of 42 months, complete response rate and event-free survival were superior among the 323 pat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Barlogie, Bart, Pineda-Roman, Mauricio, van Rhee, Frits, Haessler, Jeff, Anaissie, Elias, Hollmig, Klaus, Alsayed, Yazan, Waheed, Sarah, Petty, Nathan, Epstein, Joshua, Shaughnessy, John D., Tricot, Guido, Zangari, Maurizio, Zeldis, Jerome, Barer, Sol, Crowley, John
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2008
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2569166/
https://ncbi.nlm.nih.gov/pubmed/18492953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-03-145235
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller